Roniciclib (BAY1000394)

DRUG3 trials

Sponsors

Bayer

Conditions

NeoplasmsSmall Cell Lung Carcinoma

Phase 1

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

CompletedNCT01188252

Start: 2010-08-31End: 2016-12-31Updated: 2017-01-09

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

TerminatedNCT01573338

BayerSmall Cell Lung Carcinoma

Start: 2013-02-25End: 2016-06-23Updated: 2021-04-08

Phase 2

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

TerminatedNCT02161419

BayerSmall Cell Lung Carcinoma

Start: 2014-07-30End: 2016-05-25Updated: 2018-06-25